Day 3 at the 2017 annual meeting of the American Society of Clinical Oncology touched on immunotherapy combinations and the promise of several novel immunotherapies, including anti-IDO1 checkpoint blockade and a personalized, patient-specific vaccine. Other measures of immunotherapy’s effectiveness, such as patient quality of life, were also discussed. Below are some of the most important findings that were revealed today:
Multiple Tumor Types:
Head and Neck Cancer:
Melanoma / Skin Cancers:
Stomach & Gastrointestinal Cancer:
ASCO17: Day 2 Immunotherapy Highlights
Read Previous Article
ASCO17: Days 4 and 5 Immunotherapy Highlights
Read Next Article
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
How the video game live stream fundraiser “Prepare to Destroy Cancer” is supporting cancer immunotherapy research
How the microbiome influences the fight against cancer and what Dr. Sonnenberg hopes to accomplish during the next five years as a CRI Lloyd J. Old STAR.